Abstract
Patients with chronic kidney disease (CKD) are often 25(OH)D3 and 1,25(OH)2D3 insufficient. We studied whether vitamin D repletion could correct aberrant adipose tissue and muscle metabolism in a mouse model of CKD-associated cachexia. Intraperitoneal administration of 25(OH)D3 and 1,25(OH)2D3 (75 μg/kg/day and 60 ng/kg/day respectively for 6 weeks) normalized serum concentrations of 25(OH)D3 and 1,25(OH)2D3 in CKD mice. Vitamin D repletion stimulated appetite, normalized weight gain, and improved fat and lean mass content in CKD mice. Vitamin D supplementation attenuated expression of key molecules involved in adipose tissue browning and ameliorated expression of thermogenic genes in adipose tissue and skeletal muscle in CKD mice. Furthermore, repletion of vitamin D improved skeletal muscle fiber size and in vivo muscle function, normalized muscle collagen content and attenuated muscle fat infiltration as well as pathogenetic molecular pathways related to muscle mass regulation in CKD mice. RNAseq analysis was performed on the gastrocnemius muscle. Ingenuity Pathway Analysis revealed that the top 12 differentially expressed genes in CKD were correlated with impaired muscle and neuron regeneration, enhanced muscle thermogenesis and fibrosis. Importantly, vitamin D repletion normalized the expression of those 12 genes in CKD mice. Vitamin D repletion may be an effective therapeutic strategy for adipose tissue browning and muscle wasting in CKD patients.
Similar content being viewed by others
Introduction
Chronic kidney disease (CKD)-associated cachexia is a complex metabolic disorder that consists of anorexia, weight loss, loss of adipose tissue and muscle mass as well as hypermetabolism1,2. Current therapies focus on palliation, but calorie supplementation alone is not successful in treating CKD-associated cachexia3. Brown adipocytes and beige adipocytes, which reside within white adipose tissue (WAT), significantly contribute to whole body energy expenditure4. Beige adipocytes respond to cold stimulation in a process described as WAT browning5. We and others have demonstrated the presence of WAT browning in CKD mice5 amongst other animal disease models of cachexia as well as in patients with cachexia6,7,8,9. We also demonstrated WAT browning in a mouse model of cystinosis, a genetic cause of CKD10,11.
CKD patients have a high prevalence of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 insufficiency12,13,14. Vitamin D insufficiency2,12 may be an important cause of CKD-associated cachexia. Vitamin D influences myogenesis and muscle function15,16. Furthermore, vitamin D insufficiency has been correlated with reduced muscle size and strength in the general population. Supplementation of vitamin D was associated with increased muscle size and strength in patients on hemodialysis17. Vitamin D receptor (VDR) is expressed in skeletal muscle of mice and regulates uptake of 25-hydroxyvitamin D3 in myofibers18. Vitamin D exerts its effects via genomic and non-genomic, membrane-associated rapid response actions to regulate the function in muscle19,20. 25-hydroxyvitamin D3 could also directly exert paracrine and autocrine effects on muscle15. Low serum concentrations of 25-hydroxyvitamin D3 are an independent risk factor for decreased muscle function in elderly patients on dialysis21. Adipose tissue is an important storage site for vitamin D. Vitamin D insufficiency has been associated with aberrant adipogenesis22. There are no published data that report the direct impact of vitamin D repletion on muscle mass and adipose tissue metabolism in CKD mice. Thus, the purpose of this study was to investigate the impact of vitamin D repletion in a mouse model of CKD-associated cachexia.
Results
Vitamin D repletion normalizes serum vitamin D concentrations and improves energy homeostasis in CKD mice
Serum concentrations of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 were significantly decreased in CKD mice compared to sham (Supplemental Table 1S). Supplementation of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 (75 μg/kg/day and 60 ng/kg/day, respectively, for 6 weeks) normalized serum vitamin D concentrations in CKD mice. Vitamin D repletion normalized food intake and improved body weight gain in CKD mice (Supplemental Fig. 1S). We further evaluated the effect of vitamin D repletion beyond appetite stimulation and resultant body weight gain in CKD mice by employing a pair-feeding strategy (Supplemental Fig. 2S). CKD mice and sham control mice were treated with 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 or with vehicle, respectively. Vehicle treated CKD were fed ad libitum while other groups of mice were given the same amount of diet as vehicle treated CKD mice (Fig. 1). Results of serum chemistry of CKD mice after 6 weeks of vitamin D repletion or vehicle are shown (Table 1). Serum concentration of vitamin D binding protein (VDBP) was elevated in CKD mice versus sham mice. Repletion of vitamin D in CKD mice did not change serum VDBP levels. Circulating PTH levels were increased in CKD mice versus sham mice. Repletion of vitamin D decreased but did not normalize serum PTH levels in CKD mice. Importantly, repletion of vitamin D normalized the CKD cachexia phenotype including decreased weight gain, reduced fat mass content, elevated basal metabolic rate, and decreased lean mass (Fig. 1).
Vitamin D repletion normalizes uncoupling proteins and ATP contents as well as normalizes thermogenic gene expression in adipose tissue and muscle in CKD mice
Adipose and muscle protein contents of UCPs were higher in CKD mice compared to sham mice. In contrast, adipose and muscle ATP contents were decreased in CKD mice compared to sham mice (Fig. 2). Repletion of vitamin D normalized UCPs and ATP content in adipose and muscle tissue in vehicle treated CKD mice versus vehicle treated sham mice. Expression of adipose tissue thermogenic genes (Pgc1α, Cidea, Prdm16 and Dio2) and skeletal muscle thermogenic genes (Pparα, Pparδ, Cpt1α, Pgc1α and Pgc1β) were significantly increased in CKD mice (Fig. 2). Vitamin D repletion ameliorated elevated adipose and muscle tissue thermogenic gene expression in CKD mice.
Repletion of vitamin D attenuates adipose tissue browning in CKD mice
WAT browning occurred in CKD mice based on the presence of beige adipocyte cell markers such as the expression of thermogenic UCP-1 protein content in inguinal WAT that is normally restricted to BAT (Fig. 2). In addition, increased expression of beige adipose cell surface markers (CD137, Tmem26 and Tbx1) was measured in inguinal WAT in CKD mice (Fig. 3). Repletion of vitamin D attenuated adipose tissue browning in CKD mice. Supplementation of vitamin D normalized protein content of UCP-1 and gene expression of beige adipose cell surface markers in inguinal WAT in CKD mice (Figs. 2 and 3). Cox2/Pgf2α and inflammatory cytokines stimulate beige adipogenesis. We showed that expression of Cox2/Pgf2α and protein content of IL-1β, IL-6 and TNF were significantly increased in inguinal WAT in CKD mice versus control mice (Fig. 3). The toll-like receptor (Tlr)/NF-kB signaling pathway modulates expression of inflammatory cytokines. We show that phosphor-NF-kB p50, phosphor-NF-kB p65 and phosphor-Ikk-a protein content was significantly increased in inguinal WAT of CKD mice relative to sham mice (Fig. 3). Expression of Tlr2, myeloid differentiation primary response 88 (MyD88) and Traf6 were significantly increased in inguinal WAT in CKD mice relative to sham mice. We demonstrate that vitamin D repletion ameliorated expression of Cox2/Pgf2α as well as expression and protein content of key Tlr/NF-kB pathway molecules in inguinal WAT CKD mice relative to controls.
Vitamin D repletion improves muscle fiber size and in vivo muscle function in CKD mice
We evaluated the effect of vitamin D repletion on skeletal muscle morphology in CKD mice. Representative results of muscle sections are illustrated (Fig. 4). Repletion of vitamin D normalized average cross-sectional area of soleus and tibias anterior muscle in CKD mice. Patients with CKD are often afflicted with neuromuscular complications. We measured motor coordination in vitamin D and vehicle treated CKD mice. Vitamin D repletion normalized grip strength and rotarod fall latency in CKD mice.
Vitamin D repletion decreases muscle pro-fibrotic and increases anti-fibrotic gene expression in CKD mice
Vitamin D repletion normalized soleus collagen content in CKD mice (Fig. 4). In addition, we measured gastrocnemius muscle expression of 84 key genes involved in tissue fibrosis in mice (Supplemental Table 2S). Pro-fibrotic genes (TGFα1, PAI-1, TGIF1, IL-1α, IL-1β, Agt, CTGF, Akt1, Smad3 and Timp3) were upregulated while anti-fibrotic genes (BMP7 and IL13Rα2) were downregulated in CKD versus sham mice (Table 2). Importantly, repletion of vitamin D attenuated aberrant muscle expression of fibrotic genes in CKD mice (Table 3).
Repletion of vitamin D ameliorates muscle fat infiltration in CKD mice
We evaluated fat infiltration of the gastrocnemius muscle in mice. Representative results of Oil Red O staining of muscle section are shown (Fig. 5). We quantified intensity of muscle fat infiltration in mice and observed that vitamin D repletion attenuated muscle fat infiltration in CKD mice.
Repletion of vitamin D modulates skeletal muscle mass regulation signaling in CKD mice
Vitamin D repletion improved muscle regeneration and myogenesis by increasing gastrocnemius muscle expression of pro-myogenic factors (IGF-1, Pax7 and MyoD) and decreasing expression of negative regulators of muscle mass (Murf-1, Atrogin-1 and myostatin) as well as decreasing muscle protein contents of inflammatory cytokines IL-1β, IL-6 and TNF (Fig. 6).
Molecular mechanism by RNAseq analysis
We studied differential expression of muscle mRNA between CKD and control mice in 12-month old animals using RNAseq analysis. We identified ~ 17,000 genes in both groups. We identified 85 upregulated genes and 59 downregulated genes in CKD mice versus sham mice (Fig. 7). Identities of these differentially expressed genes (DEG) are listed in Table 4. Hierarchical clustering heatmap showed the high degree of reproducibility in samples. Detailed GO pathway analysis revealed the top differentially expressed genes are involved in cellular processes, biological regulation, and metabolic processes in CKD mice versus sham mice. An Ingenuity Pathway Analysis enrichment test revealed important pathogenetic molecular pathways related to energy metabolism, skeletal and muscular system development and function, and organismal injury and abnormalities in CKD mice relative to control mice (Fig. 8). Upregulated genes were ATP2A2, CSRP3, CYFIP2, FHL1, GNG2, MYL2, TNNC1 and TPM3 whereas downregulated genes are ATF3, FOS, ITPR1 and MAFF in CKD mice versus sham mice. The functional significance of each of these DEG is listed (Table 3). Collectively, gene expression involved in muscle and neuron regeneration is impaired in CKD mice. In addition, expression of genes involved in enhanced muscle thermogenesis and fibrosis is increased in CKD mice. We then performed qPCR analysis in the muscle specimens in the experimental mice (3 months old) in the present study. Importantly, 25(OH)D3 and 1,25(OH)2D3 repletion normalized these top 12 DEG in CKD mice in the present study (Fig. 7).
Discussion
Our results showed that CKD mice were 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 insufficient. Serum concentration of 25-hydroxyvitamin D3 status is influenced by the interplay between VDBP and free 25-hydroxyvitamin D3, which may be disrupted in the setting of CKD, perhaps from the urinary loss of VDBP. We measured serum concentrations of VDBP and 25-hydroxyvitamin D3 in mice. Interestingly, serum concentration of VDBP was elevated in CKD mice versus control mice (Table 1), implying that low free serum 25-hydroxyvitamin D3 concentrations rather than low serum VDBP is the cause of low serum total 25-hydroxyvitamin D3. This is distinct from the observation that low serum VDBP was more prevalent than low free serum concentration of 25-hydroxyvitamin D3 in CKD patients23. We then evaluated the effect of vitamin D repletion in CKD mice. Our results suggest that repletion of vitamin D attenuated adipose tissue browning and skeletal muscle wasting in CKD mice.
Hypermetabolism is a cardinal feature of cachexia in CKD1,2. Our results confirmed that hypermetabolism was present in CKD mice which was normalized by vitamin D repletion. Resting energy expenditure (REE) of CKD patients showed considerable variability, which may be influenced by degree of renal dysfunction, hyperparathyroidism, inflammation and the dialysis procedure24,25,26. Several investigations have reported that non-dialysis CKD patients have REE which may be similar or even slightly lower than that of age- and gender-matched healthy controls 27,28. These results may reflect the variable presence of cachexia in the pre-dialysis CKD population. Ikizler et al. carefully studied ESRD patients on maintenance hemodialysis and showed higher REE during resting conditions which was further increased during hemodialysis, compared with healthy controls29. Wang et al. studied a sizable population of 251 peritoneal dialysis patients, who were classified by REE tertiles. They showed that patients in the upper and middle tertiles of REE showed a significantly higher risk of all-cause mortality compared with those patients in the lower REE tertile30. Their findings highlight the significant negative prognostic effect of increased REE in CKD patients on long-term outcomes.
Adipose tissue and muscle are both involved in energy metabolism. Uncoupling protein (UCP)-1 is important for thermogenesis while UCP-2 and UCP-3 regulate mitochondrial energy metabolism31. Increased expression of adipose and muscle UCPs have been implicated in various diseased-associated cachexia6,32,33. UCPs are mitochondrial inner membrane proteins positioned in the same membrane as the ATPase, which is also a proton channel. UCPs and ATPase work in parallel with UCPs generating heat and ATP synthase generating ATP. Increased UCPs expression stimulates thermogenesis while inhibiting ATP synthesis31. Adipose tissue and muscle UCPs content was increased while adipose tissue and muscle ATP content was significantly decreased in CKD mice versus sham mice (Fig. 2). Vitamin D repletion attenuated perturbations of UCPs and ATP content in adipose tissue and muscle in CKD mice. Vitamin D insufficiency aggravates adipose tissue and muscle metabolism. 1,25-dihydroxyvitamin D3 suppresses expression of UCPs, cell differentiation as well as mitochondrial respiration in brown adipocytes33,34. Recent data also confirmed that vitamin D3 modulates UCP3 expression in muscle via the binding site consensus sequences of VDR on the UCP-3 promoter region35.
CKD mice exhibited increased expression of adipose tissue thermogenic genes (Pgc1α, Cidea, Prdm16 and Dio2) and elevated skeletal muscle gene expression involved in fatty acid oxidation (Pparα, Pparδ and Cpt1α) (Fig. 2). Fatty acids are essential elements of all cells and are important energy substrates. Increased muscle fatty acid metabolism stimulates energy expenditure and reduces mitochondrial energetics in humans36. Pgc1α, an important transcriptional coactivator, in cooperation with several other transcription factors, is involved in adipose tissue thermogenesis and muscle metabolism37,38. Increased expression of Pgc1a and its transcriptional co-activators promotes mitochondrial fatty acid oxidation and energy expenditure. In tissue where UCP-3 co-exists with UCP-2 (skeletal muscle and adipose tissue), UCP-3 and UCP-2 may act in concert in the overall regulation of fatty acid oxidation and energy expenditure39. Vitamin D repletion attenuated increased expression of both adipose tissue (Pgc1α, Cidrea, Prdm16 and Dio2) and skeletal muscle (Pparα, Pparδ, Cpt1α, Pgc1α and Pgc1β) thermogenic genes in CKD mice (Fig. 2).
We demonstrated the presence of BAT marker UCP-1 (Fig. 2) and the increased expression of beige adipocyte surface markers (CD137, Tmem26 and Tbx1) in inguinal WAT of CKD mice (Fig. 3). Repletion of vitamin D attenuated expression of these selective molecular markers of beige adipocytes in CKD mice. Cox2-associated prostaglandins act as paracrine signals and promote beige adipogenesis in inguinal WAT in mice40,41. We show that vitamin D repletion normalized over-expressed inguinal WAT Cox2 and Pgf2α mRNA level in CKD mice (Fig. 3). WAT secretes a plethora of inflammatory mediators in rodent models of cachexia. Vitamin D repletion attenuated over-expressed WAT protein content of IL-1β, IL-6 and TNF in CKD mice. Supplementation of 1,25-dihydroxyvitamin D3 decreases production of IL-1β, IL-6 and TNF in epididymal adipose tissue in mice and in human pre-adipocytes22,42,43,44. We profiled transcription factors involved in inflammatory pathways in CKD mice. Inguinal WAT of CKD mice exhibited increased expression and protein content of NFκB/TLR2 signaling pathways (NFκB p50/p65, Iκκ-α, Tlr2, MyD88 as well as Traf6). 1,25-dihydroxyvitamin D3 inhibits NFκB activation. Interaction of MyD88 and Traf6 is critical for Tlr2-mediated transactivation of NFκB and subsequent pro-inflammatory response45. We showed that repletion of vitamin D normalized inguinal WAT expression and protein content (Cox2 and Pgf2α; NF-κB p50 and p65, Tlr2, MyD88 and Traf6) and protein content of inflammatory cytokines (IL-1β, IL-6 and TNF) involved in promoting beige adipogenesis (Fig. 3). 1,25-dihydroxyvitamin D3 suppresses expression and protein content of Tlr2 in human cells46.
We studied the impact of vitamin D repletion on muscle fiber morphology and in vivo muscle function in CKD mice. To study muscle morphology, we chose to study two muscles known to have different fiber type compositions, namely soleus and tibialis anterior muscle. Soleus is a slow oxidative muscle while tibialis anterior is a fast glycolytic muscle47. Vitamin D repletion normalized average cross-sectional area of both the soleus and tibialis anterior muscles and attenuated in vivo muscle function (grip strength and rotarod activity) in CKD mice (Fig. 4). Our results are supported by previous reports that vitamin D significantly increased cross-sectional area of mouse C2C12 muscle cells48. Low vitamin D status is linked to suppressed skeletal muscle tropism and contraction15. Low serum vitamin D concentrations are associated with decreased skeletal muscle performance and an increase in the incidence of falls as well as risk of fractures17,49,50. In patients with diabetic nephropathy and CKD, treatment with paricalcitol was associated with no significant difference in glomerular filtration rate (GFR) measured directly with 51Cr-EDTA, but a significant decline in estimated GFR using an estimation formula employing serum creatinine. Serum creatinine increased significantly by a mean by 18 mmol/l despite no significant change in measured GFR, implying an increase in muscle mass in these patients51. 1,25-dihydroxyvitamin D3 increased myogenic gene expression and inhibited myostatin expression, a negative regulator of muscle mass in C2C12 cells48,52.
Muscle fat infiltration is a significant predictor of both muscle function and mobility function in older adults and across a wide variety of comorbid conditions such as diabetes, spinal cord injury and kidney disease, suggesting that increased muscle fat infiltration may at least partially account for a loss of strength and mobility seen in patients with CKD53,54,55. Muscle adipose tissue may release pro-inflammatory cytokines within the muscle and impair the local muscle environment, impair blood flow or increase the rate of lipolysis within skeletal muscle resulting in an increased concentration of glucose within the skeletal muscle itself followed by insulin resistance56,57. We evaluated the effects of vitamin D repletion on muscular fat infiltration content in CKD mice. Our results clearly demonstrated that vitamin D supplementation attenuated muscle fat infiltration in CKD mice (Fig. 5).
We investigated the impact of vitamin D repletion on signaling molecules that modulate muscle mass metabolism in CKD mice. Repletion of vitamin D attenuated the aberrant expression of genes involved in muscle regeneration (Igf1, Pax7, MyoD), proteolysis (Murf-1, Atrogin-1, myostatin) and inflammatory cytokines (IL-1β, IL-6, TNF) (Fig. 6). Myostatin impairs the growth of myocytes while stimulating the growth of muscle fibroblasts by involving the activation of several signaling pathways58. Inhibition of myostatin reverses muscle fibrosis through apoptosis58. Follistatin inhibits myostatin activity in vitro and stimulates muscle growth in vivo59. Vitamin D decreases muscle myostatin expression and increases muscle satellite cell regeneration60.
Chronic inflammation is an important factor for CKD-associated cachexia. TNF induces anorexia via peripheral and central nervous system mechanisms. Vitamin D supplementation reduced serum concentration of TNF in CKD patients12,13. Observational studies demonstrate that low serum vitamin D concentrations are correlated with increased concentrations of circulating inflammatory biomarkers such as C-reactive protein and IL-661. Supplementation of vitamin D decreased serum concentrations of inflammatory biomarkers13,61. Vitamin D modulates immunity. Vitamin D dosage-dependently inhibited NF-kB activity and reduced IL-6 and TNF production in monocytes62. Moreover, vitamin D inhibited production of pro-inflammatory cytokines and proliferation of T lymphocytes63. T-cell cytokines modulate vitamin D metabolism in monocytes64.
Recent findings suggest that increased serum levels of PTH stimulates WAT browning and muscle wasting in mouse models of CKD and cancer65. CKD mice in this study had elevated circulating PTH levels. We found that the observed improvement in muscle wasting and adipose tissue browning was accompanied by normalization of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 and attenuation of the serum PTH concentrations in CKD mice (Table 1). Serum PTH concentrations were still significantly elevated even with successful vitamin D repletion. Based on these results, we postulate that the impact of secondary hyperparathyroidism may be less significant than vitamin D insufficiency in CKD-associated WAT browning and muscle wasting. To exclude the effects of PTH in CKD-associated cachexia in our experiment, we will need to perform parathyroidectomy in mice, but this is beyond the scope of the study.
We explored the mechanistic links between vitamin D repletion and the improvement of muscle morphology and muscle function in CKD mice. Skeletal muscle fibrosis is correlated with decreased muscle inflammation and muscle weakness in CKD patients66. Importantly, we showed that vitamin D repletion normalized soleus collagen content in CKD mice (Fig. 4). We measured gastrocnemius muscle expression of 84 key genes involved in tissue fibrosis in CKD versus control mice. We showed that vitamin D repletion exerts its antifibrotic effects on skeletal muscle by inhibiting the expression of pro-fibrotic genes (TGFβ1, Agt, PAI-1 and Smad3) while stimulating the expression of anti-fibrotic genes (BMP7 and IL13Rα2) in CKD mice (Table 3).
In addition to the known action of vitamin D metabolites on regulating mitochondrial function and muscle mass regulation, it is estimated that the vitamin D–endocrine system regulates approximately 3% of the human genome67. We therefore performed muscle RNAseq analysis in gastrocnemius muscle as an unbiased, systems biology approach to the molecular mechanism of vitamin D repletion in CKD mice. We demonstrated clear differentiation in muscle transcriptomics in CKD mice versus sham mice. Deficiency of vitamin D in CKD mice alters the muscle expression of genes involved in important biological processes as listed in Fig. 7. The functional significance of each of these DEG with relevant references were listed (Table 3 with reference 68 to 79). Subsequent IPA analysis revealed the important molecular mechanisms in vitamin D deficient CKD-associated muscle wasting. Downregulation of muscle expression of ITPR1, MAFF, ATF3 and FOS have been associated with upregulation of ATP2A2. Upregulated muscle ATP2A2 expression was associated with increased beige fat thermogenesis68. Increased muscle expression of FHL1 stimulates expression of CSRP3 and as a result, promotes muscle wasting70,76. Upregulation of CYFIP2 and MYL2 stimulates muscle apoptosis via actin cytoskeleton signaling71,75. In addition, increased muscle expression of TNNC1, GNG2 and TPM3 promotes myofiber atrophy and is correlated with muscle weakness via muscle calcium signaling72,77,78 (Fig. 8). Importantly, we show that vitamin D repletion normalized those top 12 differentially expressed genes in CKD mice (Fig. 7).
In conclusion, our results showed that CKD mice were vitamin D insufficient. Repletion of vitamin D normalized serum vitamin D concentrations in CKD mice. Most importantly, repletion of vitamin D ameliorated white adipose tissue browning and muscle wasting in CKD mice (Supplemental Fig. 3S). Supplementation of vitamin D may present a mechanistically sound and inexpensive therapeutic strategy as an anti-WAT browning and anti-muscle wasting agent for patients with CKD.
Materials and methods
Experimental design
The study was in compliance with the approved animal protocol by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego. Schematic study design is listed (Supplemental Fig. 2S). Male C57BL/6 J mice at 6 weeks of age were used for the study. We surgically induced CKD in mice by performing 5/6 nephrectomy as well as performing the sham operation in control mice6. CKD and sham mice were treated with 25(OH)D3 (Sigma, Catalog 739,650-1ML, 75 μg/kg/day), 1,25(OH)2D3 (Sigma, Catalog 740,578-1ML, 60 ng/kg/day) or vehicle control (ethylene glycol) using subcutaneous osmotic Alzet 2006 pump for 6 weeks. Oxygen consumption (VO2) was measured by using Oxymax indirect calorimetry (Columbus Instrument) and lean mass and fat content of mice were analyzed by quantitative magnetic resonance method (EchoMRI-100™, Echo Medical System)6. Muscle function (grip strength and rotarod activity) in mice was assessed using grip strength meter (Model 47,106, UGO Basile) and rotarod performance test (model RRF/SP, Accuscan Instrument), respectively6.
Serum and blood chemistry
Serum concentration of bicarbonate, Ca and Pi was assessed. Concentrations of BUN, serum creatinine, 25(OH)D3, 1,25(OH)2D3, parathyroid hormone (PTH) and vitamin D binding protein (VDBP) were analyzed (Supplemental Table 4S).
Tissue adenosine triphosphate and protein levels
Adenosine triphosphate (ATP) and uncoupling protein (UCP) contents in tissue homogenates were measured. Protein contents of pro-inflammatory cytokines (IL-1β, IL-6 and TNF) in adipose and muscle tissue lysate were quantified (Supplemental Table 4S).
Muscle fiber size and muscle collagen content
Muscle fiber cross-sectional area of soleus and tibias anterior was measured6. Excised soleus muscles were hydrolyzed and hydroxyproline content was calculated (Supplemental Table 4S).
Quantification of fatty infiltration in skeletal muscle
Fresh gastrocnemius muscles were preserved in isopentane/liquid nitrogen. Dissected muscle samples were incubated with Oil Red O (Oil Red O Solution, catalog number O1391-250 ml, Sigma Aldrich). Detailed procedures for Oil Red O staining were in accordance with published protocol80. We followed a recently established protocol to quantify muscle fat infiltration. Acquisition and quantification of images were analyzed using ImageJ software (https://rsbweb.nih.gob/ij/)81.
RT2 Profiler PCR array for muscle fibrosis
Muscle fibrotic and anti-fibrotic gene expression was analyzed (Qiagen, Catalog 330,231 PAMM-120ZA). Detailed information for a total of 84 genes is listed in Supplemental Table 2S.
Muscle RNAseq analysis
We performed 5/6 nephrectomy and sham operation in 12-month old male C57BL/6 J mice. Total gastrocnemius muscle RNA was isolated in CKD and sham mice (3 mice in each group) using Trizol (Life Technology) followed by RNeasy mini kit (Qiagen) for further purification. The extracted muscle RNA samples were analyzed using Agilent 2100 Bioanalyzer (Agilent RNA 6000 Nano Kit). Samples were used to construct cDNA libraries (Illumina) and sequenced through an Illumina HiSeq2000 platform at BGI Hong Kong (www.bgi.com). The raw RNAseq data were filtered into clean reads, followed by mapping to the mouse reference genome using HISAT. The gene expression level for each sample was analyzed using RSEM quantification tool. Based on the gene expression level, differentially expressed genes (DEG) between CKD and sham mice were identified using DESeq2 algorithms. Biological function analysis of the DEG was enriched by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEEG) pathway. To identify pathways related to phenotypic differences of the muscle between CKD and sham mice, DEG between CKD and sham mice were analyzed through the use of IPA (QIAGEN Inc., https://www.qiagenbio-informatics.com/products/ingenuity-pathway-analysis)82.
Gene expression analysis
Total RNA from adipose and gastrocnemius muscle samples were isolated using TriZol (Life Technology) and reverse-transcribed with SuperScript III Reverse Transcriptase (Invitrogen). Quantitative real-time RT-PCR of target genes were performed using KAPA SYBR FAST qPCR kit (KAPA Biosystems). Expression levels were calculated according to the relative 2-DDCt method6. All primers are listed in Supplemental Table 5S.
Statistical analysis
Continuous variables are expressed as mean ± S.E.M. We assessed the statistical significance of differences between groups using two-sample t-tests. All tests were two-sided. A p value less than 0.05 was considered significant. Statistical analyses were performed using SPSS software version 16.0 for Macintosh.
References
Workeneh, B. T. & Mitch, W. E. Review of muscle wasting associated with chronic kidney disease. Am. J. Clin. Nutr. 91(Suppl), 1128S-1132S (2010).
Mak, R. H. et al. Wasting in chronic kidney disease. J. Cachexia Sarcopenia Muscle 2, 9–12 (2011).
Thomas, R., Kanso, A. & Sedor, J. R. Chronic kidney disease and its complications. Prim. Care 35, 329–344 (2008).
Sidossis, L. & Kajimura, S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J. Clin. Investig. 125, 478–486 (2015).
Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366–376 (2012).
Cheung, W. et al. Muscle wasting and adipose tissue browning in infantile nephropathic cystinosis. J. Cachexia Sarcopenia Muscle 7, 152–164 (2016).
Kir, S. & Spiegelman, B. M. Cachexia and brown fat: a burning issue in cancer. Trends Cancer 2, 461–463 (2016).
Beijer, E. et al. A role of active brown adipose tissue in cancer cachexia?. Oncol. Rev. 6, e11 (2012).
Wu, J. et al. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk. J. Cachexia Sarcopenia Muscle https://doi.org/10.1002/jcsm.12459 (2019).
Town, M. et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat. Genet. 18, 319–324 (1998).
Cheung, W. W. et al. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia. J. Cachexia Sarcopenia Muscle 11, 120–134 (2020).
Querfeld, U. & Mak, R. H. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr. Nephrol. 25, 2413–2430 (2010).
Dusso, A. S. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int. Suppl. 1, 136–141 (2011).
Holden, R. M. et al. Vitamins K and D status in stages 3–5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 590–597 (2010).
Ceglia, L. Vitamin D and its role in skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 12, 628–633 (2009).
Rejnmark, L. Effects of vitamin D on muscle function and performance: a review of evidence from randomized controlled trials. Ther. Adv. Chronic. Dis. 2, 25–37 (2011).
Gordon, O. L., Sakkas, P. K., Doyle, J. W., Shubert, T. & Johansen, K. L. The relationship between vitamin D and muscle size and strength in patients on hemodialysis. J. Ren. Nutr. 17, 397–407 (2007).
Girgis, C. M. et al. The vitamin D receptor (VDR) is expressed in skeletal muscle male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. Endocrinology 155, 327–3237 (2014).
Baran, D. T., Quail, J. M., Ray, R., Leszyk, J. & Honeyman, T. Annexin II is the membrane receptor that mediates the rapid actions of 1a,25-dihydroxyvitamin D3. J. Cell. Biochem. 78, 34–46 (2000).
Khanal, R. & Nemere, I. Membrane receptors for vitamin D metabolites. Crit. Rev. Eukaryot. Gene. Expr. 17, 31–47 (2007).
Obi, Y., Hamano, T. & Isaka, Y. Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis. Mark. 2015, 1–9 (2015).
Mutt, S. J., Hyppönen, E., Saarnio, J., Järvelin, M. R. & Herzig, K. H. Vitamin D and adipose tissue-more than storage. Front. Physiol. 5, 1–9 (2014).
Kalousova, M. et al. Vitamin D binding protein is not involved in Vitamin D deficiency in patients with chronic kidney disease. Biomed. Res. Int. 2015, 492365 (2015).
Avesani, C. M., Kaminura, M. A. & Cuppari, L. C. Energy expenditure in chronic kidney disease patients. J. Ren. Nutr. 20, 27–39 (2011).
Avesani, C. M., Draibe, S. A., Kamimura, M. A., Colugnati, P. A. B. & Cuppari, L. Resting energy expenditure of chronic kidney disease patients: influence of renal function and subclinical inflammation. Am. J. Kidney Dis. 44, 1008–1016 (2004).
Utaka, S. et al. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am. J. Clin. Nutr. 82, 801–805 (2005).
Schneeweisee, B. et al. Energy metabolism in acute and chronic renal failure. Am. J. Clin. Nutr. 52, 596–601 (1990).
Monteon, F. J., Laidlaw, S. A., Shaib, J. K. & Kopple, J. D. Energy expenditure in patients with chronic kidney failure. Kidney Int. 30, 741–747 (1986).
Ikizler, T. A. et al. Increased energy expenditure in hemodialysis patients. J. Am. Soc. Nepohrol. 7, 2646–2653 (1996).
Wang, A. Y. et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J. Am. Soc. Nephrol. 15, 3134–3143 (2004).
Rousset, S. et al. The biology of mitochondrial uncoupling proteins. Diabetes 53(Suppl 1), S130-135 (2004).
Bing, C. et al. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res. 60, 2405–2410 (2000).
Wong, K. E. et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am. J. Physiol. Endocrinol. Metab. 296, E820–E828 (2009).
Ricciardi, C. J. et al. 1,25-Dihydroxyvitamin D3/vitamin D receptor suppresses brown adipocyte differentiation and mitochondrial respiration. Eur. J. Nutr. 54, 1001–1012 (2015).
Fan, Y. et al. Vitamin D3/VDR resists diet-induced obesity by modulating UCP3 expression in muscle. J. Biomed. Sci. 23, 56 (2016).
Stephens, F. B. et al. Skeletal muscle carnitine loading increases energy expenditure, modulates fuel metabolism gene networks and prevents body fat accumulation in humans. J. Physiol. 591, 4655–4666 (2013).
Mandard, S., Müller, M. & Kersten, S. Peroxisome proliferator-activated receptor a target genes. Cell. Mol. Life Sci. 61, 393–416 (2004).
Austin, S. & St-Pierre, J. PGC1a and PGC1b, two key molecules involved in the regulation of mitochondrial energy metabolism. J. Cell. Sci. 125, 4963–4971 (2012).
Schrauwen, P. & Hesselink, M. K. The role of uncoupling protein 3 in fatty acid metabolism: Protection against lipotoxicity?. Proc. Nutr. Soc. 63, 287–292 (2004).
Vegiopoulos, A. et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 328, 1158–1161 (2010).
Zhang, X. et al. Adipose mTORC1 suppresses prostaglandin signaling and beige adipogenesis via the CRTC2-COX-2 pathway. Cell Rep. 24, 3180–2193 (2018).
Lira, F. S. et al. Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1 adipocytes following LPS stimulation. Lipids Health Dis. 10, 37 (2011).
Marcotorchino, J. et al. Vitamin D reduces the inflammatory response and restores glucose uptake in adipocytes. Mol. Nutr. Food. Res. 56, 1771–1782 (2012).
Ding, C., Wilding, J. P. & Bing, C. 1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NFkappaB and MAPK signalling and chemokine release in human adipocytes. PLoS ONE 8, e61707 (2013).
Verstak, B. et al. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4- mediated NF-kappaB proinflammatory responses. J. Biol. Chem. 284, 24192–24203 (2009).
Sadeghi, K. et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 36, 361–370 (2006).
Burkholder, T. J., Fingado, B., Baron, S. & Lieber, R. L. Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb. J. Morphol. 221, 177–190 (1994).
Girgis, C. M., Clifton-Bligh, R. J., Mokbel, N., Cheng, K. & Gunton, J. E. Vitamin D signaling regulates proliferation, differentiation, and myotube size in C2C12 skeletal muscle cells. Endocrinology 155, 347–357 (2014).
Gerdhem, P., Ringsberg, K. A., Obrant, K. J. & Akesson, K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population based OPRA study of elderly women. Osteoporos. Int. 16, 1425–1431 (2005).
Broe, K. E. et al. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J. Am. Geriatr. Soc. 55, 234–239 (2007).
Joergensen, C., Tarnow, L., Goetze, J. P. & Rossing, P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type I diabetes mellitus and diabetic nephropathy: a randomized trial. Diabetes Med. 32, 374–381 (2015).
Garcia, L. A., King, K. K., Ferrini, M. G., Norris, K. C. & Artaza, J. N. 1,25(OH)2 vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 152, 2976–2986 (2011).
Addison, O., Marcus, R.L., LaStayo, P.C., Yuan, A.S. Intermuscular fat: A review of the consequences and causes. Int. J. Endocrino. Article ID: 309570 (2014).
Goodpaster, B. H., Thaete, F. L. & Kelley, D. E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am. J. Clin. Nutr. 71, 885–892 (2000).
Cheema, B. et al. Investigation of skeletal muscle quality and quality in end-stage renal disease. Nephrology (Carlton) 15, 454–463 (2010).
Beasley, L. E. et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity 17, 1062–1069 (2009).
Sam, S. et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 32, 932–937 (2009).
Li, Z. B., Kollias, H. D. & Wagner, K. R. Myostatin directly regulates skeletal muscle fibrosis. J. Biol. Chem. 283, 18371–19378 (2008).
Lee, S. J. et al. Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998–2008 (2010).
Braga, M., Simmons, Z., Norris, K. C., Ferrini, M. G. & Artaza, J. N. Vitamin D induces myogenic differentiation in skeletal muscle derived stem cells. Endocr. Connect. 6, 139–150 (2017).
Yin, K. & Agrawal, D. K. Vitamin D and inflammatory diseases. J. Inflamm. Res. 7, 69–87 (2014).
Zhang, Y. et al. Vitamin D inhibits monocyte/macrophage pro-inflammatory cytokine production by targeting mitogen-activated protein kinase phosphatase 1. J. Immunol. 188, 2127–2135 (2012).
Calton, E. K., Keane, K., Newsholme, P. & Soares, M. J. The impact of vitamin D levels on inflammatory status: a systemic review of immune cell studies. PLoS ONE 10, e141770 (2015).
Edfeldt, K. et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc. Natl. Acad. Sci. U. S. A. 107, 22593–22598 (2010).
Kir, S. et al. PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23, 315–323 (2016).
Abramowitz, W. K. et al. Skeletal muscle fibrosis is associated with decreased muscle inflammation and weakness in patients with chronic kidney disease. Am. J. Physiol. Renal Physiol. 315, F1658–F1669 (2018).
Bouillon, R., Gielen, E. & Vanderschueren, D. Vitamin D receptor and vitamin D action in muscle. Endocrinology 155, 3210–3213 (2014).
Ikeda, K. et al. UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis. Nat. Med. 23, 1454–1465 (2017).
Kannan, M. B. et al. The small MAF transcription factors MAFF, MAFG and MAFK: current knowledge and perspective. Biochem. Biophys. Acta 1823, 18411–18416 (2012).
Vafiadaki, E. et al. Muscle lim protein isoform negatively regulates striated muscle actin dynamic and differentiation. FEBS J. 281, 3261–3279 (2014).
Sheikh, F. et al. Functions of myosin light chain-2 in cardiac muscle and disease. Gene 569, 14–20 (2015).
Juretić, N. et al. Differential gene expression in skeletal muscle cells after membrane depolarization. J. Cell. Physiol. 210, 819–830 (2007).
Kami, K. et al. Localization of myogenin, c-fos, c-jun, and muscle-specific gen mRNAs in regenerating rat skeletal muscle. Cell Tissue Res. 280, 11–19 (1995).
Linda, H. et al. Activating transcription factor 3, a useful marker for regenerative response after nerve root injury. Front. Neurol. 2, 30 (2011).
Saller, E. et al. Increased apoptosis induction by 121F mutant p53. EMBO J. 18, 4424–4437 (1999).
Lee, J. Y. et al. FHL1 activates myostatin signaling in skeletal muscle and promotes atrophy. FEBS Open Bio 5, 753–762 (2015).
Jin, Y. et al. Comprehensive analysis of tropomyosin isoforms in skeletal muscles by top-down proteomics. J. Muscle Res. Cell Motil. 37, 41–52 (2016).
Heinonen, S. et al. Adipocyte morphology and implications for metabolic derangements in acquired obesity. Int. J. Obest. (Lond.) 38, 1423–1431 (2014).
Suman, M. et al. Inositol trisphosphate receptor-mediated Ca2+ signalling stimulates mitochondrial function and gene expression in core myopathy patients. Hum. Mol. Genet. 27, 2367–2382 (2018).
Dubowitz, V. Histological and histochemical stains and reactions. In Muscle biopsy. A practical approach 4th edn (eds Dubowitz, V. et al.) (Elsevier, Amsterdam, 2013).
Mehlem, A., Hagberg, C. E., Kuhl, L., Eriksson, U. & Falkwvall, A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat. Protoc. 8, 1149–1154 (2013).
Kramer, A., Green, J., Pollard, J. Jr. & Tugedreich, S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30, 523–530 (2014).
Acknowledgements
We thank Dr. Jianhua Shao, UCSD Pediatric Diabetes Research Center for the use of EchoMRI-100™. The authors thank James A. Proudfoot for his assistance in statistical analysis. This project was partially supported by the National Institutes of Health (NIH), UL1TR001442 of CTSA funding. This project was funded by National Institutes of Health Grant R01 DK125811 to RHM and U01DK03012 to RLL and RHM, Shanghai Pujiang Program 17PJD021 and distinguished Young Scholar of Ninth People’s Hospital jyyq09201701 (W D), Nature Scientific Foundation of Heilongjiang Province (LC2017034) and Research fund for Young and Middle-aged Innovative Science of the Second Affiliated Hospital of Harbin Medical University (CX2016-03) (P Z), Yangzhou University Overseas Study Program (S L) and National Institutes of Health R24-HD050837 (R L L). This work was also supported in part by Research Career Scientist Award Number IK6 RX003351 from the United States (U.S.) Department of Veterans Affairs Rehabilitation R&D (Rehab RD) Service.
Author information
Authors and Affiliations
Contributions
W.W.C and R.H.M conceived study and designed experiments. W.W.C, W.D, Z.W, S.H, R.Z, A.G, J.Y.Z, P.Z, S.L, and M.C.E performed experiments. W.W.C, R.L.L and R.H.M interpreted results and analyzed the data. W.W.C, H.M.H, R.L.L and R.H.M wrote the manuscript. All authors reviewed and approved the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Cheung, W.W., Ding, W., Hoffman, H.M. et al. Vitamin D ameliorates adipose browning in chronic kidney disease cachexia. Sci Rep 10, 14175 (2020). https://doi.org/10.1038/s41598-020-70190-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-020-70190-z
- Springer Nature Limited
This article is cited by
-
The Different Shades of Thermogenic Adipose Tissue
Current Obesity Reports (2024)
-
Bone marrow mesenchymal stem cell exosomes suppress phosphate-induced aortic calcification via SIRT6–HMGB1 deacetylation
Stem Cell Research & Therapy (2021)
-
The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia
Scientific Reports (2021)